Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Status:
Completed
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this research is to evaluate the effectiveness and safety of a combination of
capecitabine, temozolomide and bevacizumab in the treatment of advanced pancreatic
neuroendocrine tumors.